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Altering the Regiospecificity of C6 Indole Prenyltransferases Towards Drug Development 
by Ahmed R Aoun 
 
Prenyltransferase (PT) biocatalysts are late-stage tailoring enzymes that modify natural 
products. PTs catalyze the attachment of prenyl moieties to natural product acceptors using 
pyrophosphate donors. This prenyl modification in small molecules leads to changes in 
structural and biological activities. Understanding the structural insights as well as the 
mechanisms by which PTs function allows us to utilize PTs as a unique approach towards 
drug development. PriB PT is an example of aromatic PTs that has been characterized 
previously as a L-tryptophan (L-Trp) C6 C-prenyltransferase (C6-C-PT). Analysis of PriB 
binding pocket, highlighted key residues that might play an important role in determining 
the regiospecificity of the enzyme and their mechanisms. Hence, we hypothesized that site-
directed mutagenesis of one of these residues will alter the enzyme regiospecificity and/or 
its permissiveness leading to variation in the pharmacokinetics and biological activities of 
small molecules. Site-directed mutagenesis approach was used to engineer PriB PT as a 
model for C6-PTs and the purified mutant proteins were produced and purified. In vitro 
reactions of the purified engineered proteins have shown altered regiospecificity toward 
substrate acceptors when compared to wild type. The long-term goal for this study is to 
utilize the permissiveness of PriB enzyme for drug diversification and determine the 
activity of the mutant PriB enzymes. This study will also shed some light on the 
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1.1. The Progress of Natural Products Discovery 
Natural products (NPs), have been used as different treatment options for many severe diseases. 
The majority of the active ingredients of medicines are obtained from natural sources, such as 
plants, animals, fungi, and microorganisms (Newman & Cragg, 2016). The diversity in the 
chemical structures and the efficacy of NPs have served as essential approaches to understanding 
the cell physiology (Wilkinson & Micklefield, 2007). Many pharmaceutical companies, during the 
last few decades, have shifted to synthetic compounds rather than NPs in drug discovery due to 
several limitations including traditional NPs screening techniques which frequently led to the 
rediscovery of already known compounds and inconsistency of NP production from their natural 
sources. Furthermore, the minute quantities of NPs obtained from their natural sources, which 
requires large quantities of the original source, high labor costs for extraction and purifications, as 
well as time-consuming processes are additional hurdles. Moreover, the complexity of natural 
products makes the characterization of their structures a challenging task not preferable for 
medicinal chemists (Lam, 2007).  
 
Nevertheless, the innovation of NP discovery methods, such as new methodology in production, 
purification, and characterization, has influenced numerous pharmaceutical industries to regain 
interest in this field. Furthermore, with the development of new screening assays and targets 
combined with the new chemical entities that NPs provide, have increased the interest in NP 
discovery (Katz & Baltz, 2016). For example, Novartis Institutes for BioMedical Innovation 




Argyrin B, and antibacterial antiparasitic. Cyclomarin A (Schmitt et al., 2016). Mutational 
biosynthesis also is another approach for the development of novel NPs through the insertion of 
analogs of NP intermediates into biosynthetic pathways; for instance, the production of 
nikkomycin antibiotic from novobiocin analogs (Weist & Süssmuth, 2005).  
 
During the last three decades, there have been two fundamental scientific progressions that had an 
essential impact on NP discovery. These advancements, include the detailed understanding of NP 
biosynthesis, and the development of genetic tools for Streptomycetes. The diverse NP structures 
are synthesized through a complex system of enzymatically catalyzed metabolic pathways. 
Enzymes from natural product biosynthetic pathways have become fascinating approaches for 
modifying the bioactivities of these complex molecules especially after the evolution of NPs 
biosynthesis technology and the identification of biosynthetic gene clusters and encoding enzymes 
(Ncube et al., 2017) (Medema et al., 2015). In addition, Streptomycetes have exposed a significant 
and adjustable group of bacteria for the production of diverse valuable secondary metabolites. 
These secondary metabolites have brought attention in numeral medicinal companies and 
academia after the development of recombinant DNA (rDNA) technology. These advancements 
include plasmid vectors, protoplast transformation, and engineering strategies as well as the 
development of analytical approaches such as proteomics and metabolomics  (Bekker et al., 2014) 
(Bro & Nielsen, 2004) (Katz & Baltz, 2016). Improvement of DNA cloning and sequencing have 
assisted in understanding the biochemical pathways of NPs via resolving and predicting the 
enzymes that are involved in the biosynthesis from NPs genes sequences or gene cluster. 
Clustering enables the cloning of the whole NP biosynthesis pathway into vectors and heterologous 




Combinatorial biosynthesis is a method to manufacture a sequence of elected potential drugs for 
high-throughput screening. This approach has been used for the generation of “unnatural” NPs 
especially those biosynthesized by nonribosomal peptide synthetase (NRPS) and polyketide 
synthase (PKS) genes, which are involved in the biosynthesis of polyketides (PKs) and 
nonribosomal peptides (NRPs), respectively, possess essential antibiotic, anticancer, and 
immunosuppressant activities (Menzella & Reeves, 2007) (Yin et al., 2007) (Weissman, 2015).  
 
1.2. Tailoring Enzymes and Chemoenzymatic Reactions 
The decoration of NPs by chemical moieties such as hydroxyls, methyls, sugars, and halogens is 
crucial for the modification of these compounds and leads to the enhancement of their 
pharmacological activities and properties. These groups are added by a group of enzymes that are 
encoded within the biosynthetic gene cluster of the NP and are collectively called tailoring 
enzymes. Enzymes, such as methyltransferases, cytochrome P450s, halogenases, 
glycosyltransferases, prenyltransferases, are examples of tailoring enzymes (Lin et al,. 2012). 
Tailoring enzymes can be utilized as valuable tools for the targeted modification of molecules and 
drugs and can complement chemical methods to generate novel compounds (Alwaseem et al,. 
2018) (S. Mori et al,. 2019) (Newmister et al., 2018) (Hughes et al., 2017).  
 
Enzyme catalysis is one of the powerful tools to modify small molecules and has become 
frequently used in the chemical industry and scientific research due to multiple reasons. 
Biocatalysts are efficient, usually produce regiospecific products, under greener, milder, and safer 
conditions for the modification of bioactive compounds (González-Sabín et al., 2011) (Wells et 




aqueous conditions with minimum side products (Romney et al, 2018). Chemoenzymatic 
reactions, enzymatic modification, along with synthetic methods, has succeeded to produce 
biologically active compounds such as analogs of the antibiotics daptomycin, vancomycin, and 
pristinamycin (Grünewald & Marahiel, 2006).  
 
1.3. Prenyltransferase Enzymes 
Prenyltransferase (PT) biocatalysts are tailoring enzymes used to catalyze the attachment of prenyl 
moieties from pyrophosphate substrates (donors) to various aliphatic or aromatic acceptors via 
nucleophilic substitution (Figure 1). Examples of natural pyrophosphate donor substrates include 
the pyrophosphates of dimethylallyl (DMAPP, C5), geranyl (GPP, C10), farnesyl (FPP, C15), or 
geranylgeranyl (GGPP, C20). Acceptor substrates include low and high molecular weight small 
molecules, nucleic acids, peptides, and proteins (Winkelblech, Fan, & Li, 2015). Furthermore, 
protein prenyltransferases are significant for the post-translational modification of proteins in 
living organisms and demonstrate essential drug targets (Heide, 2009).  
 
Figure 1. The catalyzed reaction of aromatic PTs 
 
The SN1 reaction of dimethylallyl pyrophosphate (DMAPP) is initiated by the release of the 
pyrophosphate moiety as a good leaving group and the cleavage of carbon-oxygen (C1-OPP) bond 




C1 and C3 of the prenyl group (Figure 2). The prenyl cation attaches to the nucleophiles in the 




Figure 2. Release of OPP group lead to carbocation intermediate on C1 or C3	
	
 
Dimethylallyltryptophan synthase (DMATS) superfamily are aromatic PTs (ArPTs) and is one of 
the most investigated enzyme subgroups. They share sequence homology with the DMATSs 
involved in the biosynthesis of ergot alkaloids in Claviceps purpurea (Tsai et al., 1995). Until 
2015, more than 40 such enzymes have been determined and characterized biochemically 
(Winkelblech et al., 2015). The majority of the DMATS superfamily members are involved in the 
biosynthesis of prenylated indole alkaloids and modify indole derivatives as acceptors including, 
tryptophan and tryptophan-containing cyclic dipeptides as substrates (Winkelblech et al., 2015). 
One interesting feature of DMATSs and other ArPTs is their relatively broad acceptor 
permissiveness allowing them to accommodate various substrates. Thus, using these enzymes in 
drug modification could, in some instances, provide a more efficient and environmentally friendly 









1.4. Importance of Prenylation and Regiospecificity 
Many published studies demonstrated the bioactivity of prenylated natural products (Alhassan et 
al., 2014). The advantages of the presence of a prenyl moiety in various natural compounds include 
enhancing the target protein binding affinity as well as improving the interaction with cell 
membrane/cell wall compared to the nonprenylated counterparts (Botta et al., 2005). Prenylation 
in small molecules leads to changes in structural and biological activities. Prenylation opens the 
door for a unique approach towards drug development and provides new chemical libraries for 
pharmacological screening (Botta et al., 2005).	 Biosynthesis of many biologically active 
compounds in animals and plants depends on aromatic secondary metabolite prenylation (Alhassan 
et al., 2014). Examples of prenylated bioactive compounds include novobiocin, clorobiocin, 








One study examined the antiproliferative activity of nonprenylated naringenin and prenylated 
flavonoids [(Xanthohumol and four prenylflavonoids: 8-prenylnaringenin, 6-prenylnaringenin 
isoxanthohumol, and α,β-dihydroxanthohumol) (Figure 4)] against different human cancer cell 
line (Bartmańska et al., 2018). The outcome of this study exhibited that prenylated naringenins 
had higher anticancer activity compared to nonprenylated naringenin. Moreover, this study pointed 
out the significance of the position of prenylation, where there were changes in activity and 
































































































antiproliferative activity, except breast cancer cell line, where 6-prenyl analog exhibited higher 
activity and selectivity (Bartmańska et al., 2018). Furthermore, other previous study showed that 
adding prenyl group to the cyclic lipopeptide antibiotic daptomycin increased the antimicrobial 
activity against gram-positive bacteria compared to nonprenylated daptomycin (Elshahawi et al., 
2017). Furthermore, the mode of prenylation, normal versus reverse, also affects the activity of the 
drugs (Elshahawi et al., 2017).  
 
Another advantage of PTs is their ability to catalyze carbon-carbon bond formation. Generally, 
different PTs have been characterized as capable of catalyzing the transfer of the prenyl moiety to 
all carbon positions of the indole ring. Noticeably, PTs catalyze the formation of a carbon-carbon 
bond between the indole ring and the prenyl group in milliseconds (Tanner, 2015). Carbon-carbon 
bond formation in organic synthesis is a crucial step to build up complex structure compounds 
from smaller molecules. Generating complex products have tremendous applications. 
Nevertheless, it is very challenging to approach this via synthetic methods because it requires 
intricate approaches for chiral synthesis (for non-aromatic moieties), multiple protection and 




Thus, this indicates the significance of prenyl moieties for improving the pharmacological activity 








1.5. Enzyme Engineering  
Biochemical reactions in aqueous media are fundamental for life; however, in synthetic chemistry, 
the existence of water in chemical reactions could lead to negative impacts, including minimizing 
yields and productivity. Certainly, removing even minute quantities of water from chemical 
reactions is sometimes a challenging task for most chemists (Arnold, 2018). Most reactions in 
chemical syntheses require organic solvents, which produce toxic wastes that affect safety and the 
environment. Therefore, replacement of reactions running in organic solvents with substitutes that 
work in aqueous media is a hot topic in research. Moreover, water-based reactions provide an 
essential boundary between chemistry and biology, which allow making chemical modifications 
of biomolecules. This leads to the improvement of biotherapeutic medicines such as bioactive 
peptides, drug conjugated antibody, biopharmaceuticals, and small molecule derivatives from 























natural products. Mainly, none of these accomplished would be achievable without aqueous 
reactions because most biological molecules are unstable and insoluble in organic media (Romney 
et al., 2018). 
 
Recently, several pharmaceutical and biotechnological industries started incorporating natural 
enzymes for many fundamental reactions. Yet, many natural biocatalysts do not exhibit the desired 
stability and efficiency to proceed with the industrial requirements (Kokkonen et al., 2019). 
Nowadays, the advancement of biotechnology has brought new techniques to improve and produce 
enzymes with desirable properties. Protein engineering such as site-directed mutagenesis is one of 
the approaches that can alter amino acids residues at specific enzyme sites. In the last two decades, 
enzyme engineering has succeeded in modifying enzymes with higher activities than wild-type 
enzymes (Bilal et al., 2018). Furthermore, enzyme engineering demonstrated the ability to improve 
the stability and catalytic activity towards non-native substrates (Bornscheuer et al., 2012) 
(Almhjell et al., 2018). Enzyme engineering has also led to catalyzing reactions that were restricted 
only by synthetic catalysts (Hammer et al., 2017) (Zhang et al., 2019). Various engineered 
enzymes have exhibited significant improvement in selectivity and activity during biological 
reactions (Hammer et al., 2017) (Cho et al., 2019).  
 
Previous studies on the PTs engineering showed that site-directed mutagenesis on some PT amino 
acid residues changed the catalytic activity and improved the acceptance of other substrates. One 
study published in 2017 showed that site-directed mutagenesis of a DMATS superfamily member, 
FtmPT1 (Gly115 and Tyr205 to other residues), led to altering the prenylation position and 




published in 2015, demonstrated that a mutant FgaPT2 (Lys174 to Phe) had altered the substrate 
preference (L-Trp) to another substrate, L-Tyr (Fan et al., 2015). 
 
Other researches have also studied the role of other active site residues to improve the substrate 
permissiveness, Fan and colleagues have shown enhancing the activity of aromatic 
prenyltransferase FgaPT2 acceptance toward cyclic dipeptide substrate, R244 has been replaced 
with other amino acids. Notably, mutation of R244 with amino acid leucine significantly improved 
the product yield with cyclic dipeptide substrate comparing with other mutants; however, the result 
of R244 mutants which tested with the native substrate L-Trp decreased or abolished the activity. 
Clearly, this outcome showed the importance of R244 as a key residue to maintain the L-Trp 
substrate by hydrogen bonding to the carboxylate group of L-Trp (Fan & Li, 2016). Moreover, in 
a previous study, site-directed mutagenesis on TleC and MpnD aromatic PTs have changed the 
enzyme activity and the preferences of prenyl group length of the substrate. The structural analysis 
of the binding pocket of both enzymes demonstrated that Trp97, Ala173 in TleC have replaced 
with Tyr80, Met159 in MpnD. In TleC, mutation of Trp97 to Tyr and Ala173 to Met have affected 
the donor preferences comparing with TleC wild-type. The Trp97 to Tyr replacement enhanced 
the activity of C5 DMAPP substrate preferences than the preferred donor C10 GPP. Moreover, the 
Ala173 Met mutant increased the acceptance toward C5 DMAPP, whereas C10 GPP is no longer 
accepted. In MpnD PT mutation of Tyr80 to Trp and Met159 to Ala increased the C10 prenylation 
and whereas the prenylation of C5 decreased compared with wild-type (T. Mori et al., 2016). 
Structure alignment of PriB PTs with the other previous studied PTs have shown similarity among 
them. This suggests that to perform alteration of substrate (donors/ acceptors) selectivity for PriB, 




1.6. PriB Prenyltransferases 
PriB PT is an aromatic PTs that was characterized from the genome of a bacterial strain 
Streptomyces sp. (actinomycetes), which was separated from the soil near a thermal vent of Ruth 
Mullins coal fire in the Appalachian Mountains (Elshahawi et al., 2017; Wang et al., 2015). PriB 
protein belong to the DMATS superfamily characterized with a barrel shape (β-barrel) composed 
of αββα units. The PriB is composed of a cylindrical β-sheet arranged around a ring of solvent-
exposed α-helices (Figure 5) (Elshahawi et al., 2017).  PriB was characterized as an L-Trp C6 C-
prenyltransferase (C-PT) (Elshahawi et al., 2017, Fan, Winkelblech, & Li, 2015). PriB’s 
permissiveness is not limited to acceptors but also extends to donor substrates. PriB is one of few 
DMATS enzymes that is capable of accommodating not only DMAPP and L-Trp (native donor 
and acceptor, respectively), but also various non-native donors (geranyl, farnesyl, geranylgeranyl 
and other synthetic diphosphates) and other aromatic acceptor substrates including, anthranilic 
acid, naphthalenes, anthraquinones, phenazines, and D-Trp with high conversion percentages. PriB 
PT was also found to prenylate the drug pindolol (Visken®) and the antibiotic daptomycin 





Figure 5. The X-ray ternary crystal structure of PriB enzyme with substrates, L-Trp (acceptor) and DMSPP (donor 
analog) in yellow sticks 
	
In this study, the examination of the binding pocket of PriB X-ray crystal structure (Figure 6) 
showed that both the native donor and acceptor are in proximity with multiple residues including 
His312, Tyr380, Leu110, Trp165, Tyr181, Tyr364, Arg316, Phe220, and Leu293.  
 
A basic amino acid residue suggests that it could be playing a role in the catalysis of the C6 
nucleophilic substitution reaction (Murakami et al., 2006; Guillén Schlippe & Hedstrom, 2005; 
Metzger et al., 2009). Furthermore, we determined that the closest position of the nitrogen atom 
of the imidazole ring of His312 is with C6 L-Trp (3.7 Å) (Figure 7). Also, the structure alignments 
of PriB with other non C-6 PTs, AnaPT (C3-reverse, PDB ID 4LD7) TleC (C7-reverse, PDB ID 
4YZL), MpnD (C7-reverse, PDB ID 4YLA), FgaPT2 (C3-normal, PDB ID 3I4X), FtmPT1(C2-
normal, PDB ID 3O2K), and CdpNPT (C3-reverse, PDB ID 4E0U) showed the H312 in PriB are 
aligned with Tyr residues in these enzymes (Figure 9).  Thus, we propose that site-directed 




regiospecificity. The goal of this work is to investigate the role of His312 in the regiospecificity 
of PriB and other C-6 indole PTs. This work will also shed some light on the mechanistic insights 





Figure 6. Exhibit close up view of the binding pocket, the binding pocket shows that both L-Trp and DMSPP 
(yellow sticks) in close proximity to each other and to PriB multiple residues (purple sticks). 
	
	










Figure 9. Structure alignment of PriB (C6-normal, PDB ID 5INJ), AnaPT (C3-reverse, PDB ID 4LD7) TleC (C7-
reverse, PDB ID 4YZL), MpnD (C7-reverse, PDB ID 4YLA), FgaPT2 (C3-normal, PDB ID 3I4X), FtmPT1(C2-
normal, PDB ID 3O2K), and CdpNPT (C3-reverse, PDB ID 4E0U) indole PTs showing conserved His312 in C-6-C-
PTs representing another evidence of the involvement of His312 residue in the C6 prenylation regiospecificity. The 
























































2.1. Strains and Materials 
PriB plasmid was obtained as a gift from the University of Kentucky, Center for Pharmaceutical 
Research and Innovation, Natural Products Repository. E. coli 5α and BL21 (DE3) competent cells 
were purchased from New England Biolabs. All reagents and chemicals were purchased from 
Sigma-Aldrich or Fisher Scientific. LB Broth (Miller) and LB Broth with agar (Lennox) were 
obtained from Sigma Aldrich (St. Louis, Missouri). DNA primers were obtained from Integrated 
DNA Technologies, Inc. (Coralville, Iowa). All mutations were sequence verified at Retrogen, Inc 
(San Diego, California) or ACGT, Inc (Wheeling, Illinois). Gene analysis and alignments were 
performed using Geneious 11.1.5. 
 
2.2. Plasmid Purification  
The PriB plasmid was transformed into E. coli 5α cells and streaked on a plate containing LB agar 
and kanamycin with final concentration 80 µg mL-1. The transformed cells were incubated at 37°C 
for 16 hr followed by inoculation into liquid medium (LB broth with kanamycin) at 37°C with 250 
rpm for 16 hr. The cell pellet was collected by centrifugation at 4,500 ×g for 10 min. Genomic 
DNA was purified using Monarch® Nucleic Acid Purification Kits (New Englands BioLabs®) 
following the manufacturer’s protocol. DNA quality and quantity were assessed using gel 
electrophoresis and Nanodrop (Thermo Scientific NanoDrop 2000 1-position Spectrophotometer). 
 
2.3. Site Directed Mutagenesis  
In order to perform site-directed mutagenesis, the primers of PriB_H312 were designed using 




Mutagenesis Kit (New Englands BioLabs®) was performed following the manufacturer’s protocol 
and transformed into 5α cells. Purified plasmids were isolated, purified and quantified. Quality of 
purified plasmids were assessed by measuring the A260/280 and A260/230. Plasmids of suitable 
quantity and high quality were sent for DNA sequencing. The correct plasmids, as confirmed by 
sequencing, were transformed into BL21(DE3) incubated onto LB agar with kanamycin (80 µg 
mL-1) plates and incubated overnight at 37°C. After checking the cells growth, one colony from 
each strain was inoculated into 15 mL culture tube containing 4 mL liquid medium (LB with 
kanamycin, 80 µg mL-1) and incubated for 16 hr, at 37°C, 250 rpm. Glycerol stocks of each 
construct containing 15% glycerol were stored in at −80°C for future use.  
 
Table 1. Designed primers in order to mutate PriB_H312. Residues targeting His312 residue are underlined. 
 
 
DNA Primer Sequences 
PriB_H312A-F 5’-CTA CAC CCT CGC TGT GCC GGT CCG CGA CTA CGT CCG G-3’ 
PriB_H312R-F 5’-CTA CAC CCT CAG AGT GCC GGT CCG CGA CTA CGT CCG-3’ 
PriB_H312N-F 5’-CTA CAC CCT CAA TGT GCC GGT CCG CGA CTA C-3’ 
PriB_H312D-F 5’-CTA CAC CCT CGA TGT GCC GGT CCG CGA CTA C-3’ 
PriB_H312C-F 5’-CTA CAC CCT CTG TGT GCC GGT CCG CGA CTA CGT CCG G-3’ 
PriB_H312Q-F 5’-CTA CAC CCT CCA AGT GCC GGT CCG CG-3’ 
PriB_H312E-F 5’-CTA CAC CCT CGA AGT GCC GGT CCG CGA CTA CG-3’ 
PriB_H312G-F 5’-CTA CAC CCT CGG TGT GCC GGT CCG CGA CTA CGT CCG G-3 
PriB_H312I-F 5’-CTA CAC CCT CAT TGT GCC GGT CCG CGA CTA CGT CCG G-3’ 
PriB_H312L-F 5’-CTA CAC CCT CTT AGT GCC GGT CCG CGA CTA CGT CCG G-3’ 





2.4. Protein Production 
LB broth (1L) supplemented with kanamycin (80 µg mL-1) was inoculated with 0.3% (v/v) of an 
overnight PriB_H312_X (Phe, Lys, Arg, Trp, Tyr) E. coli BL21 (DE3) at 37°C with shaking (250 
rpm). Cultures were induced at OD600 of ~ 0.6–0.8 with isopropyl-β-D-thiogalactopyranoside 
(IPTG, 0.5 mM final concentration) and allowed to grow for an additional 16 hr at 23°C. The cells 
were centrifuged, harvested and stored at −80°C until used. The proteins of other mutant 
PriB_H312M-F 5’-CTA CAC CCT CAT GGT GCC GGT CCG CGA CTA CGT CCG GCA CGA CGG-
3’ 
PriB_H312F-F 5’-CTA CAC CCT CTT TGT GCC GGT CCG CGA CTA CGT CCG G -3’ 
PriB_H312P-F 5’-CTA CAC CCT CCC TGT GCC GGT CCG CGA CTA CGT CC-3’ 
PriB_H312S-F 5’-CTA CAC CCT CTC AGT GCC GGT CCG CGA CTA CGT CCG GCA C-3’ 
PriB_H312T-F 5’-CTA CAC CCT CAC TGT GCC GGT CCG CGA CTA CGT CCG GCA C-3’ 
PriB_H312W-F 5’-CTA CAC CCT CTG GGT GCC GGT CCG CGA CTA CGT CCG G-3’ 
PriB_H312Y-F 5’-CTA CAC CCT CTA TGT GCC GGT CCG CGA C-3’ 
PriB_H312V-F 5’-CTA CAC CCT CGT AGT GCC GGT CCG CGA CTA CGT CCG GCA CG -3’ 
PriB_H312X-R 5’-CCG CTG GGC CGC CCG GTC-3’ 
6DMATSsa_H284Y-F 5’-CTT TAC CTT GTA TAT TCC GGT TCG TGA TTA TG-3’ 
6DMATSsa_H284Y-R 5’-CCG CTC GGA CGA CCA CTG-3’ 
6DMATSsv_H287Y-F 5’-TTA TAC GCT GTA TGT TCC CGT AAG-3’ 
6DMATSsv_H287Y-R 5’-CCA GAA GGA AGG CCA GTT-3’ 
6DMATSmo_H329Y-F 5’-TCT GAT CGC GTA TGT TTC TCT GCG-3’ 
6DMATSmo_H329Y-R 5’-CCA ACA CCG TCA CGC AGC-3’ 
6DMATSmo_Y277H-F 5’-TTA CTC TAT CCA TGT TCC GAT CCG TTC TTA CGT TAC C-3’ 




PriB_H312 plasmids were expressed following the same procedure, but on a small scale using 250 
mL baffled flasks containing 100 mL LB/kanamycin. 
 
2.5. Protein Purification 
All following steps were carried out on the ice. Cells were allowed to thaw then subsequently lysed 
by sonication (Virtis VirSonic 475 with a microtip, 100W, 10 × 10 sec pulses, 20 sec between 
pulses). Insoluble debris was removed by centrifugation at 15,000 ×g for 1 hr. The supernatants 
were collected and filtered using 0.22 µm filters, and the desired N-His6-PriB mutant fusion 
proteins were purified via HiTrap nickel-nitrilotriacetic acid (Ni-NTA, Sigma) affinity 
chromatography using standard protocols with NGC™ 10 Medium-Pressure Chromatography 
Systems (BIO-RAD). Buffer exchange of each sample were performed using a PD-10 column (GE 
Healthcare) eluted with 50 mM Tris, 100 mM NaCl, pH 8.0 to yield the desired mutant PriB 
proteins. Fractions were collected and concentrated using Amicon Ultra Centrifuge columns 
30,000 MWCO (EMD Millipore) and stored in 50 mM Tris, 100 mM NaCl, glycerol 10%, pH 8.0 
at −80°C. Protein concentrations were determined by Bradford assay (Bio-Rad) using bovine 
serum albumin as a standard. Purity and presence of proteins were confirmed by SDS-PAGE gel 
(Blot™ 4-12% Bis-Tris Plus, Invitrogen) electrophoresis. The images of the gels were taken by 
ChemiDocTM Imaging system (Bio-Rad). 
  
2.6. HPLC Methods 
HPLC Method A—The method was developed on Shimadzu UHPLC (RX-SHMADZU-9020-
Instrument). SUPELCO® Titan C-18 (1.9 µm, 15 cm × 2.1 mm) column (Sigma-Aldrich) [7% B 




second, 7% B for over 4 min (A = ddH2O with 0.1% formic acid; B = acetonitrile with 0.1% 
formic acid) flow rate = 0.4 mL/min; A280]. Injection volume 20 µL.  
HPLC Method B —The method was developed on Bruker Q-TOF LC/MS (HPLC). SUPELCO® 
Titan C-18 (1.9 µm, 5 cm × 2.1 mm) column (Sigma-Aldrich) [7% B for 2 min, gradient of 7% B 
to 100% B for 5 min, 100% B for 3 min, 100% B to 7% B for 20 second, 7% B for over 4 min (A 
= ddH2O with 0.1% formic acid; B = acetonitrile with 0.1% formic acid) flow rate = 0.4 mL/min; 
A280]. Injection volume 10 µL. 
HPLC Method C— The method was developed on Shimadzu analytical HPLC (Prominence i, 
LC-2030 3D). Supelco Ascentis® C-18 (5 µm, 25 cm × 10 mm) column (Sigma-Aldrich) [17% B 
for 140 min, isocratic, (A = ddH2O with 0.1% formic acid; B = acetonitrile with 0.1% formic acid) 
flow rate = 4 mL/min; A280]. 
 
2.7. In Vitro Characterization of Mutant Proteins  
Mutant PriB in vitro assays were conducted in PCR tubes (200 µL) in a volume of 25 µL Tris 50 
mM (pH 8.0) containing a final concentration of 0.5 mM L-Trp, 0.5 mM DMAPP, and 1 µM PriB 
mutant. After pre-incubation of the reaction mixture at 37°C for 10 min, the reactions were initiated 
by the addition of enzyme and allowed to proceed for 16 hrs at 37°C. Reactions with positive and 
negative reactions with and without the wild type of PriB respectively were performed under the 
same conditions. The reactions were quenched by the addition of 25 µL MeOH and mixing 
followed by centrifugation (22,000 ×g, 15 min, 4°C) to remove precipitated protein. The 
supernatants were analyzed by HPLC-PDA using Method A and mass using Method B were used 





2.8. Large Scale in Vitro Reaction for Mutant Protein  
For isolation and full characterization of prenylated L-Trp analogs, 1 mL reactions (×50) in 1.5 mL 
Eppendorf tubes containing 2.5 mM acceptor (L-Trp), 2.5 mM DMAPP, 12.5 µM mutant enzyme 
in 50 mM Tris (pH 8.0) were incubated for 16 hr at 37°C. Reactions were combined, terminated 
by mixing with an equal volume of MeOH, centrifuged to remove precipitated protein and dried 
under reduced pressure.  
 
2.9. Generation of 6-DMATSxx Mutants 
Codon optimized constructs of 6-DMATSMo, 6-DMATSSa, and 6-DMATSSv were synthesized by 
Twist Bioscience (San Francisco, CA) and ligated into pET28a plasmids. Plasmids were purified 
as described with PriB. Site-directed mutagenesis was performed in the active site of other C-6 
ArPTs including 6-DMATS Sa_H284Y, 6-DMATS Sv_H287Y, and 6-DMATSMo (Y277H, H329Y, 
and double mutant Y277H_H329Y). The corresponding 6-DMATSxx proteins were produced and 
purified with the same methods described for PriB-H312X mutants. Proteins production were 








RESULTS and DISCUSSION 
3.1. Site Directed Mutagenesis  
Saturation mutagenesis has been performed on PriB_H312 to mutate it to all other 19 amino acid 
residues. Thus we obtained PriB_H312X where X = Ala (A), Cys (C), Asp (D), Glu (E), Phe (F), 
Gly (G), Ile (I), Lys (K), Leu (L), Met (M), Asn (N), Pro (P), Gln (Q), Arg (R), Ser (S), Thr (T), 
Val (V), Trp (W) & Tyr (Y). The DNA mutants of the mutated PTs were confirmed by DNA 
sequencing (Figure 10).  
 
	
Figure 10. Representative sequencing results of some amino acids (Lys, Trp) showing successful mutations. 
 
3.2. Protein Production and Purification 
Attempts to produce all 19 PriB_H312X mutants were performed followed by purification using 
Ni-NTA resin column (Figure 11). The mutant proteins culture yield (other than Tyr mutant) were 




mL-1. The PriB mutant proteins were analyzed by SDS-PAGE (Figure 12). Only two mutants 
(PriB_H312D and PriB_H312P) did not show the protein bands. This lack of protein production 
indicates possible toxicity or stability issues. The molecular weight of the PriB was consistent with 
the calculated weight (43.34 kDa).  
  
	
Figure 11. FPLC elution profile of PriB_H312Y crude protein. Column (Ni-NTA, Sigma) affinity chromatography. 
Buffer A: 10 mM Imidazole, 50 mM KH2PO4, 300 mM NaCl (pH 8.0). Buffer B: 250 mM Imidazole, 50 mM KH2PO4, 






              
 





3.3. In Vitro Characterization of Mutant Proteins  
HPLC analysis of the incubation mixture of L-Trp, DMAPP with PriB_H312Y protein showed 
that the enzymatic reaction produces more than one product in contrast to wild-type PriB which 
produces only one product 6-dimethylallyltryptophan (6-DMAT) (Figures 14 and 15) as previously 
reported (Elshahawi et al., 2017). Other PriB_H312X either lacked activity or produce minimal 
conversion than wild type except for PriB_H312X (G, E, and Q) where their conversion yield 
similar to wild type (Figure 13). Figure 16 exhibited LC-MS data of PriB (WT) and PriB_H312Y 
prenylated compound. The chromatogram PriB WT shows only one compound eluted at 5.7 min 
with observed mass [M+H]+ 273.1602, whereas the PriB_H312Y shows 3 compounds in different 
retention time 5.3 min, 5.4 min, and 5.7 min, with observed mass [M+H]+ 273.1588, 273.1596, 

















Figure 13. HPLC analysis of the PriB_H312X-mutants (other than Tyr) products, showed no new products  

































Figure 15. The enzyme products from the large-scale reaction was isolated and injected to HPLC (17% ACN, 0.1% 
FA for 140 min) to separate and collect the compounds using Method C 
 
Figure 14. HPLC identification of the enzyme products of PriB and H\Y mutant. The enzymatic reaction consists 
of 50 mM Tris/ HCl (pH 8.0) including 0.5 mM L-Trp, 1 mM DMAPP, with 1 µM enzyme using Method A 
 























































































3.4. Q-TOF Mass (LC-MS) 
  
Figure 16. LC-MS spectra of PriB-WT and PriB-H312Y showed that the PriB-WT has only 1 prenylated compound 
with mass [M+H]+ 273.1602. PriB-H312Y showed 3 compounds in different retention times (5.3 min, 5.4 min, and 
















3.5. Analysis of Binding Pockets of other C-6 PT 
To see if the switch of the His residue to Tyr will provide the same results in other C-6-indole PTs 
could lead to the same PriB_H312Y results. Three C-6-indole PTs including 6-
dimethylallyltryptophan synthase from bacteria S. ambofaciens (6-DMATSSa), 6-
dimethylallyltryptophan synthase from bacteria S. violaceusniger (6-DMATSSv), and 
dimethylallyltryptophan synthase from bacteria M. olivasterospora (6-DMATSMo) were reported 
previously (Winkelblech & Li, 2014) (Winkelblech, Xie, & Li, 2016). However, no crystal 
structures are deposited in PDB. Thus, we generated homology models for the three proteins using 
SWISS-MODEL software. The structural alignment of these C-6-PTs have shown that His312 
residue in PriB corresponds to H284 and H287 in 6-DMATSSa and 6-DMATSSv, respectively, but 
it corresponds to Y277 in 6-DMATSmo. However, 6-DMATSMo has a His residue in the binding 




Figure 17. Structural alignment of PriB and homology models of 6-DMATSSa, 6- DMATSSv, and 6-DMATSMo. (B) A 
close up of His312 residue in PriB, and corresponding residues in other 6-DMATS enzymes showing the presence of 
His in 6- DMATSSa and 6-DMATSSv but Tyr in 6-DMATSMo. (C) Histidine residue in 6-DMATSMo aligns with a Tyr 




3.6. Mutation of other C6-C-PTs 
Site-directed mutagenesis was performed in the active site of other C-6 ArPTs including 6-
DMATSSa_H284Y, 6-DMATSSv_H287Y, and 6-DMATSMo (Y277H, H329Y, and double mutant 
Y277H and H329Y). The corresponding proteins were produced and purified. The presence of 6-
DMATSx PTs (WT, and mutants) proteins were established via SDS-Page (Figure 18). The 
molecular weight of the 6-DMATS Sa, 6-DMATS Sv and 6-DMATSMo enzymes were 39.91 kDa, 
40.87 kDa, and 40.59 kDa, respectively. HPLC analysis of the His mutant of the 6-indole-PTs 
utilizing the PriB_H312Y reaction condition, demonstrated His mutation to Tyr in these enzymes 
seems to produce compounds other than C-6 normal prenylated compound (Figure 19). Table 2 
summarized the histidine\ tyrosine mutagenesis on the active site of PriB, 6-DMATS Sa, 6-DMATS 




























Figure 19. HPLC identification of the enzyme products of DMATS (sa, sv, mo) and their mutants. The enzymes (1 






Table 2. Summary of histidine and tyrosine mutations on ArPTs 
 
C-6 ArPT enzymes PriB_H312 position PriB_Y364 position Products 
PriB (WT) His312 Tyr364 1 product 
6-DMATSSa (WT) His284 Tyr336 1 product 
6-DMATSSv (WT) His287 Tyr339 1 product 
6-DMATSMo (WT) Tyr277 His329 More than 1 product 
PriB_H312Y Tyr312 Tyr364 ~ 4 products 
6-DMATSSa_H284Y Tyr284 Tyr336 ~ 4 products 
6-DMATSSv_H287Y Tyr287 Tyr339 ~ 4 products 
6-DMATSMo_Y277H His277 His329 1 product 
6-DMATSMo_H329Y Tyr277 Tyr329 ~ 4 products 
6-DMATSMo_dm His277 Tyr329 1 product 
 
Structural analysis and site-directed mutagenesis have assisted in understanding the role of some 
residues within the PT active site as well as changing the regiospecificity or substrate selectivity. 
A previous study in FgaPT2 showed the role of acid-base residues during prenylation (Glu89 and 
Lys174) (Figure 21). FgaPT2_Glu89 probably have a significant role in enhancing the 
electrophilic substitution reaction of the L-Trp indole nucleus by forming a hydrogen bond between 
the indole N-H and the carboxylate group of Glu89. Mutation of Glu89 to alanine has completely 
abolished the activity, which shows the importance of this residue in the reaction mechanism 
(Metzger et al., 2009). FgaPT2_Glu89 corresponds to PriB_Glu94 (Figure 21). The Glu89 in 
FgaPT2 also corresponds to other PTs such as Glu116 in CdpNPT, Glu102 in FtmPT1, Glu89 in 




this position in most PTs. FgaPT2_Lys174 is placed conveniently in the catalytic binding pocket 
to catalyze prenylation during the formation of the final prenylated product. Furthermore, the 
indole ring of L-Trp substrate and the aromatic ring of Tyr345 in FgaPT2 sandwich the prenyl 
moiety of DMAPP. These interactions maintain the carbocation intermediate via cation– 
π interactions which expedite the first ionization stride (Tanner, 2015). Substitution of Lys174 to 
other residue diminished the activity of the biocatalysts. Interestingly, mutation of Lys174 to 
alanine has produced a new compound by changing the prenylation from normal C-4 to reverse C-
3 (Luk et al., 2011).  
 
In this study, we have analyzed the PriB PTs active site. Among all the key residues that surround 
the substrate, we have chosen the potential residue that could control the regiospecificity, which 
we proposed to be His312. Noticeably, histidine residue is conserved in other C-6 prenylation PTs, 
for instance, 6-DMATSSa and 6-DMATSSv. Also, the proximity of the basic residue His312 to C-
6 of the indole ring in the L-Trp substrate, and the role of the basic residue histidine that seems to 
play a major role in the mechanism of reaction in ArPTs enzymes make it the first candidate for 
mutagenesis. Figure 20 demonstrates a proposed mechanism of the PriB enzymatic reaction based 
on the previous study on FgaPT2 enzyme. We propose that Glu94 will form a hydrogen bond with 
the nearby nitrogen atom of the Trp indole ring. Moreover, we propose that His312 plays a role as 
a general base by abstracting the proton from the indole ring during catalysis (Figure 21) as the 
case with FgaPT2_Lys174.  It is worth to mention that histidine and tyrosine residues have shown 
significant roles in the catalysis mechanism in other enzymes (non-PT). For example, two histidine 
residues (His47, His12) have shown essential role in the acid-base reaction mechanism of 
sphingomyelinases D (spider venom) to hydrolyze sphingomyelin (Murakami et al., 2006). In 




reductase enzyme. The Tyr166 donate a proton to the C4 atom during substrate reduction. 
Remarkably, replacement of Tyr166 to phenylalanine generated a new compound 3-decenoyl-CoA 
instead of 2,4-dienoyl-CoA (Tu et al., 2008). These studies show the significance of His and Tyr 




Figure 20. Theoretical enzymatic catalysis of DMATS in PriB 
 
 
Figure 21. A (PriB), and B (FgaPT2) shows that both E94 (PriB) and E89 (FgaPT2) carboxylate group bind to 
indole N-H via hydrogen bond (2.7 Å for both enzymes), also the nearest amino acid residues H312 and K174 to  
the prenylation position C-6 (3.7 Å) for PriB and C-4 (3.2 Å) for FgaPT2 
 
Figure 22 shows the structure alignment of PriB wt and PriB_H312Y. There are different 




























































play a role in the catalytic reaction as proposed in Figure 20, is strategically distant from C-6 only 
on the indole ring and not other sites. Mutation of His to the larger aromatic ring in Tyr would 
extend to other C position such as C-5 and C-7. [2] the phenyl ring of Tyr (6- membered ring) 
differ than His imidazole ring (5- membered ring), therefore the π−π  interactions of the Tyr 
residue could shift the substrate positions allow to produce different isomers. [3] His has been 
shown to abstract and donate protons during catalysis while Tyr role donates a proton. This 
suggests that a different mechanism might have occurred to produce the other derivatives. [4] 
His312 could be participating in attacking the DMAPP (donor) and stabilizing normal prenylation, 
whereas Tyr could stabilize normal/reverse or only reverse prenylation.  
 
The rationale behind the fact that the activity of His312 mutants such as Gly, Glu, and Gln did not 
affect the catalytic activity is unclear, and it needs further study to understand the role of these 
mutations in catalysis. 
 
 







This study exhibited the importance of His312 in the catalytic mechanism of PriB PTs. Structure-
based enzyme engineering on PriB His312 to Tyr successfully altered the prenylation preference 
from C-6 normal to form other isomers. Also, His mutation on other C-6 indoles PTs 6-DMATSSa, 
6-DMATSSv, and 6-DMATSMo demonstrated other than single prenylated compound. Indeed, 
further work needed to finish this study, including purification and characterization of the newly 
formed compounds. Future goals would be to examine the permissiveness of mutant PriB enzymes 
for drug diversification purposes.  
 
 



















Alhassan, A. M., Abdullahi, M. I., Uba, A., & Umar, A. (2014). Prenylation of Aromatic 
Secondary Metabolites: A New Frontier for Development of Novel Drugs. Tropical 
Journal of Pharmaceutical Research, 13(2), 307–314. 
Almhjell, P. J., Boville, C. E., & Arnold, F. H. (2018). Engineering enzymes for noncanonical 
amino acid synthesis. Chemical Society Reviews, 47(24), 8980–8997. 
https://doi.org/10.1039/c8cs00665b 
Alwaseem, H., Frisch, B. J., & Fasan, R. (2018). Anticancer activity profiling of parthenolide 
analogs generated via P450-mediated chemoenzymatic synthesis. Bioorganic & 
Medicinal Chemistry, 26(7), 1365–1373. https://doi.org/10.1016/j.bmc.2017.08.009 
Arnold, F. H. (2018). Directed Evolution: Bringing New Chemistry to Life. Angewandte Chemie 
International Edition, 57(16), 4143–4148. https://doi.org/10.1002/anie.201708408 
Bartmańska, A., Tronina, T., Popłoński, J., Milczarek, M., Filip-Psurska, B., & Wietrzyk, J. 
(2018). Highly Cancer Selective Antiproliferative Activity of Natural Prenylated 
Flavonoids. Molecules, 23(11), 2922. https://doi.org/10.3390/molecules23112922 
Bekker, V., Dodd, A., Brady, D., & Rumbold, K. (2014). Tools for metabolic engineering in 
Streptomyces. Bioengineered, 5(5), 293–299. https://doi.org/10.4161/bioe.29935 
Bilal, M., Iqbal, H. M. N., Guo, S., Hu, H., Wang, W., & Zhang, X. (2018). State-of-the-art 
protein engineering approaches using biological macromolecules: A review from 
immobilization to implementation view point. International Journal of Biological 




Bornscheuer, U. T., Huisman, G. W., Kazlauskas, R. J., Lutz, S., Moore, J. C., & Robins, K. 
(2012). Engineering the third wave of biocatalysis. Nature, 485(7397), 185–194. 
https://doi.org/10.1038/nature11117 
Botta, B., Monache, G. D., Menendez, P., & Boffi, A. (2005). Novel prenyltransferase enzymes 
as a tool for flavonoid prenylation. Trends in Pharmacological Sciences, 26(12), 606–
608. https://doi.org/10.1016/j.tips.2005.09.012 
Botta, B., Vitali, A., Menendez, P., Misiti, D., & Delle Monache, G. (2005). Prenylated 
flavonoids: Pharmacology and biotechnology. Current Medicinal Chemistry, 12(6), 717–
739. 
Bro, C., & Nielsen, J. (2004). Impact of “ome” analyses on inverse metabolic engineering. 
Metabolic Engineering, 6(3), 204–211. https://doi.org/10.1016/j.ymben.2003.11.005 
Cho, I., Jia, Z.-J., & Arnold, F. H. (2019). Site-selective enzymatic C‒H amidation for synthesis 
of diverse lactams. Science (New York, N.Y.), 364(6440), 575–578. 
https://doi.org/10.1126/science.aaw9068 
Elshahawi, S. I., Cao, H., Shaaban, K. A., Ponomareva, L. V., Subramanian, T., Farman, M. 
L., … Singh, S. (2017). Structure and specificity of a permissive bacterial C-
prenyltransferase. Nature Chemical Biology, 13(4), 366–368. 
https://doi.org/10.1038/nchembio.2285 
Fan, A., & Li, S.-M. (2013). One Substrate – Seven Products with Different Prenylation 
Positions in One-Step Reactions: Prenyltransferases Make it Possible. Advanced 
Synthesis & Catalysis, 355(13), 2659–2666. https://doi.org/10.1002/adsc.201300386 
Fan, A., & Li, S.-M. (2016). Saturation mutagenesis on Arg244 of the tryptophan C4-




tryptophan-containing cyclic dipeptides. Applied Microbiology and Biotechnology, 
100(12), 5389–5399. https://doi.org/10.1007/s00253-016-7365-3 
Fan, A., Winkelblech, J., & Li, S.-M. (2015). Impacts and perspectives of prenyltransferases of 
the DMATS superfamily for use in biotechnology. Applied Microbiology and 
Biotechnology, 99(18), 7399–7415. https://doi.org/10.1007/s00253-015-6813-9 
Fan, A., Zocher, G., Stec, E., Stehle, T., & Li, S.-M. (2015). Site-directed mutagenesis switching 
a dimethylallyl tryptophan synthase to a specific tyrosine C3-prenylating enzyme. The 
Journal of Biological Chemistry, 290(3), 1364–1373. 
https://doi.org/10.1074/jbc.M114.623413 
González-Sabín, J., Morán-Ramallal, R., & Rebolledo, F. (2011). Regioselective enzymatic 
acylation of complex natural products: Expanding molecular diversity. Chemical Society 
Reviews, 40(11), 5321–5335. https://doi.org/10.1039/C1CS15081B 
Grünewald, J., & Marahiel, M. A. (2006). Chemoenzymatic and Template-Directed Synthesis of 
Bioactive Macrocyclic Peptides. Microbiology and Molecular Biology Reviews, 70(1), 
121–146. https://doi.org/10.1128/MMBR.70.1.121-146.2006 
Guillén Schlippe, Y. V., & Hedstrom, L. (2005). A twisted base? The role of arginine in enzyme-
catalyzed proton abstractions. Archives of Biochemistry and Biophysics, 433(1), 266–278. 
https://doi.org/10.1016/j.abb.2004.09.018 
Hammer, S. C., Knight, A. M., & Arnold, F. H. (2017). Design and evolution of enzymes for 





Heide, L. (2009). Prenyl transfer to aromatic substrates: Genetics and enzymology. Current 
Opinion in Chemical Biology, 13(2), 171–179. 
https://doi.org/10.1016/j.cbpa.2009.02.020 
Hughes, R. R., Shaaban, K. A., Zhang, J., Cao, H., Phillips, G. N., & Thorson, J. S. (2017). OleD 
Loki as a Catalyst for Tertiary Amine and Hydroxamate Glycosylation. Chembiochem: A 
European Journal of Chemical Biology, 18(4), 363–367. 
https://doi.org/10.1002/cbic.201600676 
Katz, L., & Baltz, R. H. (2016). Natural product discovery: Past, present, and future. Journal of 
Industrial Microbiology & Biotechnology, 43(2), 155–176. 
https://doi.org/10.1007/s10295-015-1723-5 
Kokkonen, P., Bednar, D., Pinto, G., Prokop, Z., & Damborsky, J. (2019). Engineering enzyme 
access tunnels. Biotechnology Advances. 
https://doi.org/10.1016/j.biotechadv.2019.04.008 
Lam, K. S. (2007). New aspects of natural products in drug discovery. Trends in Microbiology, 
15(6), 279–289. https://doi.org/10.1016/j.tim.2007.04.001 
Lin S, Huang T, & Shen B. (2012). Tailoring Enzymes Acting on Carrier Protein-Tethered 
Substrates in Natural Product Biosynthesis. Methods in Enzymology, 516, 321–343. 
https://doi.org/10.1016/B978-0-12-394291-3.00008-3 
Luk, L. Y. P., Qian, Q., & Tanner, M. E. (2011). A Cope Rearrangement in the Reaction 
Catalyzed by Dimethylallyltryptophan Synthase? Journal of the American Chemical 




Medema, M. H., Kottmann, R., Yilmaz, P., Cummings, M., Biggins, J. B., Blin, K., … Glöckner, 
F. O. (2015). Minimum Information about a Biosynthetic Gene cluster. Nature Chemical 
Biology, 11, 625–631. https://doi.org/10.1038/nchembio.1890 
Menzella, H. G., & Reeves, C. D. (2007). Combinatorial biosynthesis for drug development. 
Current Opinion in Microbiology, 10(3), 238–245. 
https://doi.org/10.1016/j.mib.2007.05.005 
Metzger, U., Schall, C., Zocher, G., Unsöld, I., Stec, E., Li, S.-M., … Stehle, T. (2009). The 
structure of dimethylallyl tryptophan synthase reveals a common architecture of aromatic 
prenyltransferases in fungi and bacteria. Proceedings of the National Academy of 
Sciences of the United States of America, 106(34), 14309–14314. 
https://doi.org/10.1073/pnas.0904897106 
Mori, S., Pang, A. H., Thamban Chandrika, N., Garneau-Tsodikova, S., & Tsodikov, O. V. 
(2019). Unusual substrate and halide versatility of phenolic halogenase PltM. Nature 
Communications, 10(1), 1255. https://doi.org/10.1038/s41467-019-09215-9 
Mori, T., Zhang, L., Awakawa, T., Hoshino, S., Okada, M., Morita, H., & Abe, I. (2016). 
Manipulation of prenylation reactions by structure-based engineering of bacterial 
indolactam prenyltransferases. Nature Communications, 7. 
https://doi.org/10.1038/ncomms10849 
Murakami, M. T., Freitas Fernandes-Pedrosa, M., de Andrade, S. A., Gabdoulkhakov, A., Betzel, 
C., Tambourgi, D. V., & Arni, R. K. (2006). Structural insights into the catalytic 
mechanism of sphingomyelinases D and evolutionary relationship to 
glycerophosphodiester phosphodiesterases. Biochemical and Biophysical Research 




Ncube, B., Ndhlala, A. R., & Van Staden, J. (2017). Secondary Metabolism and the Rationale for 
Systems Manipulation. In S. Jha (Ed.), Transgenesis and Secondary Metabolism (pp. 45–
65). https://doi.org/10.1007/978-3-319-28669-3_23 
Newman, D. J., & Cragg, G. M. (2016). Natural Products as Sources of New Drugs from 1981 to 
2014. Journal of Natural Products, 79(3), 629–661. 
https://doi.org/10.1021/acs.jnatprod.5b01055 
Newmister, S. A., Romminger, S., Schmidt, J. J., Williams, R. M., Smith, J. L., Berlinck, R. G. 
S., & Sherman, D. H. (2018). Unveiling sequential late-stage methyltransferase reactions 
in the meleagrin/oxaline biosynthetic pathway. Organic & Biomolecular Chemistry, 
16(35), 6450–6459. https://doi.org/10.1039/c8ob01565a 
Romney, D. K., Arnold, F. H., Lipshutz, B. H., & Li, C.-J. (2018). Chemistry Takes a Bath: 
Reactions in Aqueous Media. The Journal of Organic Chemistry, 83(14), 7319–7322. 
https://doi.org/10.1021/acs.joc.8b01412 
Schmidt, N. G., Eger, E., & Kroutil, W. (2016). Building Bridges: Biocatalytic C–C-Bond 
Formation toward Multifunctional Products. ACS Catalysis, 6(7), 4286–4311. 
https://doi.org/10.1021/acscatal.6b00758 
Schmitt, E. K., Hoepfner, D., & Krastel, P. (2016). Natural products as probes in pharmaceutical 
research. Journal of Industrial Microbiology & Biotechnology, 43(2), 249–260. 
https://doi.org/10.1007/s10295-015-1691-9 
Tanner, M. E. (2015). Mechanistic studies on the indole prenyltransferases. Natural Product 
Reports, 32(1), 88–101. https://doi.org/10.1039/c4np00099d 
Tsai, H. F., Wang, H., Gebler, J. C., Poulter, C. D., & Schardl, C. L. (1995). The Claviceps 




alkaloid biosynthesis. Biochemical and Biophysical Research Communications, 216(1), 
119–125. https://doi.org/10.1006/bbrc.1995.2599 
Tu, X., Hubbard, P. A., Kim, J.-J. P., & Schulz, H. (2008). Two Distinct Proton Donors at the 
Active Site of Escherichia coli 2,4-Dienoyl-CoA Reductase Are Responsible for the 
Formation of Different Products. Biochemistry, 47(4), 1167–1175. 
https://doi.org/10.1021/bi701235t 
Walsh, C. T. (2014). Biological Matching of Chemical Reactivity: Pairing Indole Nucleophilicity 
with Electrophilic Isoprenoids. ACS Chemical Biology, 9(12), 2718–2728. 
https://doi.org/10.1021/cb500695k 
Wang, X., Reynolds, A. R., Elshahawi, S. I., Shaaban, K. A., Ponomareva, L. V., Saunders, M. 
A., … Thorson, J. S. (2015). Terfestatins B and C, New p-Terphenyl Glycosides 
Produced by Streptomyces sp. RM-5–8. Organic Letters, 17(11), 2796–2799. 
https://doi.org/10.1021/acs.orglett.5b01203 
Weissman, K. J. (2015). The structural biology of biosynthetic megaenzymes. Nature Chemical 
Biology, 11(9), 660–670. https://doi.org/10.1038/nchembio.1883 
Weist, S., & Süssmuth, R. D. (2005). Mutational biosynthesis—a tool for the generation of 
structural diversity in the biosynthesis of antibiotics. Applied Microbiology and 
Biotechnology, 68(2), 141–150. https://doi.org/10.1007/s00253-005-1891-8 
Wells, A. S., Finch, G. L., Michels, P. C., & Wong, J. W. (2012). Use of Enzymes in the 
Manufacture of Active Pharmaceutical Ingredients—A Science and Safety-Based 
Approach To Ensure Patient Safety and Drug Quality. Organic Process Research & 




Wilkinson, B., & Micklefield, J. (2007). Mining and engineering natural-product biosynthetic 
pathways. Nature Chemical Biology, 3(7), 379–386. 
https://doi.org/10.1038/nchembio.2007.7 
Winkelblech, J., Fan, A., & Li, S.-M. (2015). Prenyltransferases as key enzymes in primary and 
secondary metabolism. Applied Microbiology and Biotechnology, 99(18), 7379–7397. 
https://doi.org/10.1007/s00253-015-6811-y 
Winkelblech, J., & Li, S.-M. (2014). Biochemical investigations of two 6-DMATS enzymes 
from Streptomyces reveal new features of L-tryptophan prenyltransferases. 
Chembiochem: A European Journal of Chemical Biology, 15(7), 1030–1039. 
https://doi.org/10.1002/cbic.201400046 
Winkelblech, J., Xie, X., & Li, S.-M. (2016). Characterisation of 6-DMATSMo from 
Micromonospora olivasterospora leading to identification of the divergence in 
enantioselectivity, regioselectivity and multiple prenylation of tryptophan 
prenyltransferases. Organic & Biomolecular Chemistry, 14(41), 9883–9895. 
https://doi.org/10.1039/c6ob01803c 
Yin, J., Straight, P. D., Hrvatin, S., Dorrestein, P. C., Bumpus, S. B., Jao, C., … Walsh, C. T. 
(2007). Genome-Wide High-Throughput Mining of Natural-Product Biosynthetic Gene 
Clusters by Phage Display. Chemistry & Biology, 14(3), 303–312. 
https://doi.org/10.1016/j.chembiol.2007.01.006 
Zhang, R. K., Chen, K., Huang, X., Wohlschlager, L., Renata, H., & Arnold, F. H. (2019). 
Enzymatic assembly of carbon-carbon bonds via iron-catalysed sp3 C-H 




Zhou, K., Zhao, W., Liu, X.-Q., & Li, S.-M. (2016). Saturation mutagenesis on Tyr205 of the 
cyclic dipeptide C2-prenyltransferase FtmPT1 results in mutants with strongly increased 
C3-prenylating activity. Applied Microbiology and Biotechnology, 100(23), 9943–9953. 
https://doi.org/10.1007/s00253-016-7663-9 
  
